Leveraging AI & Big Data in Microbiome Drug Discovery
Time: 2:00 pm
day: Conference Day One, Track One, PM
Details:
- Analyzing gut microbiome data is incredibly challenging due to the wide variation in microbial ecosystems found in the gut and due to the incredible explosion of scientific papers linking the gut microbiome to various diseases and health conditions (now more than two thousand peer-reviewed studies per month in PubMed). For the first time, large language models (a form of AI) offer us the ability to synthesize all of the world’s scientific knowledge to fully analyze gut microbiome data for an individual. 1:30 Impact of Vaginal Products on the Vaginal Microbiome
- Regulatory insights into clinical assessments during clinical trials
- Clinical trial data showcasing contraceptive studies and impact on the microbiome
- New approaches to Improving vaginal health David Friend, Chief Scientific Officer, Daré Bioscience 2:00 Roundtable Discussion: Harnessing the Microbiome for Women’s Health: Advancing Research, Diagnostics & Therapeutics
- The Role of the Microbiome in Female Health – Exploring how the vaginal, gut, and skin microbiomes influence conditions like bacterial vaginosis, recurrent UTIs, endometriosis, PCOS, and pregnancy outcomes
- Bridging the Gap Between Research & Clinical Translation – How can we accelerate microbiome-based discoveries into clinically validated treatments?
- The extraction of the complete published scientific knowledge of the microbiome makes it possible to develop a microbiome digital twin that can be used to digitally simulate the effects of different interventions on a trial subject with a known microbiome and predict drug therapeutic efficacy prior to treatment in the trial
- This AI technology for both analysis and digital twinning unlocks new opportunities and avenues for drug targets, therapeutic development, clinical trial design, patient recruitment and biomarker development
